Tom Nilsen1,2, Kathrin Sunde2, Lars-Olof Hansson1, Aleksandra Mandic Havelka3, Anders Larsson1. 1. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 2. Gentian AS, Moss, Norway. 3. Department of Molecular Medicine and Surgery, Karolinska Institute and Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND: Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays is the rather long test-turnaround times. A particle enhanced turbidimetric immunoassays (PETIA) for fecal calprotectin would reduce test-turnaround times and would permit more laboratories to perform the measurements. The aim of this study was to evaluate a new feces calprotectin PETIA. METHOD: Using routine fecal samples the feces calprotectin PETIA was validated on two chemistry analyzers, Mindray BS-380 and Cobas 501. RESULTS: The assay is linear in the range 11-2000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10 000-15 000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3%-8% in the 50-100 μg/g range. CONCLUSION: The fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are commutable with Bühlmann fecal MRP8/14 ELISA.
BACKGROUND: Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays is the rather long test-turnaround times. A particle enhanced turbidimetric immunoassays (PETIA) for fecal calprotectin would reduce test-turnaround times and would permit more laboratories to perform the measurements. The aim of this study was to evaluate a new feces calprotectin PETIA. METHOD: Using routine fecal samples the feces calprotectin PETIA was validated on two chemistry analyzers, Mindray BS-380 and Cobas 501. RESULTS: The assay is linear in the range 11-2000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10 000-15 000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3%-8% in the 50-100 μg/g range. CONCLUSION: The fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are commutable with Bühlmann fecal MRP8/14 ELISA.
Authors: N Waugh; E Cummins; P Royle; N-B Kandala; D Shyangdan; R Arasaradnam; C Clar; R Johnston Journal: Health Technol Assess Date: 2013-11 Impact factor: 4.014
Authors: Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: F Costa; M G Mumolo; M Bellini; M R Romano; L Ceccarelli; P Arpe; C Sterpi; S Marchi; G Maltinti Journal: Dig Liver Dis Date: 2003-09 Impact factor: 4.088
Authors: Nicholas A Kennedy; Annalie Clark; Andrew Walkden; Jeff C W Chang; Federica Fascí-Spurio; Martina Muscat; Brydon W Gordon; Kathleen Kingstone; Jack Satsangi; Ian D R Arnott; Charlie W Lees Journal: J Crohns Colitis Date: 2015-01 Impact factor: 9.071
Authors: Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet Journal: United European Gastroenterol J Date: 2021-05-07 Impact factor: 4.623
Authors: Stephan R Vavricka; Henriette Heinrich; Simon Buetikofer; Flavia Breitenmoser; Emanuel Burri; Xiaoye Schneider-Yin; Jasmin Barman-Aksoezen; Luc Biedermann; Michael Scharl; Jonas Zeitz; Gerhard Rogler; Benjamin Misselwitz; Matthias Sauter Journal: United European Gastroenterol J Date: 2018-05-28 Impact factor: 4.623